Publications scientifiques en 2010

Depuis le 31/03/2025
  1. False discovery rate estimation for frequentist pharmacovigilance signal detection methods.
    Ahmed I, Dalmasso C, Haramburu F, Thiessard F, Broët P, Tubert-Bitter P.
    Biometrics. 2010
  2. Medical and non-medical direct costs of chronic low back pain in patients consulting primary care physicians in France.
    Depont F, Hunsche E, Abouelfath A, Diatta T, Addra I, Grelaud A, Lagnaoui R, Molimard M, Moore N.
    Fundam Clin Pharmacol. 2010
  3. Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation.
    Couzi L, Levaillant Y, Jamai A, Pitard V, Lassalle R, Martin K, Garrigue I, Hawchar O, Siberchicot F, Moore N, Moreau JF, Dechanet-Merville J, Merville P.
    J Am Soc Nephrol. 2010
  4. Medicine or ecstasy? The importance of the logo.
    Daveluy A, Miremont-Salamé G, Rahis AC, Delile JM, Bégaud B, Gachie JP, Haramburu F.
    Fundam Clin Pharmacol. 2010
  5. Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting.
    Molimard M, Le Gros V, Robinson P, Bourdeix I.
    J Aerosol Med Pulm Drug Deliv. 2010
  6. Easily available adjustment criteria for the comparison of antibiotic consumption in a hospital setting: experience in France.
    Amadeo B, Dumartin C, Robinson P, Venier AG, Parneix P, Gachie JP, Fourrier-Réglat A, Rogues AM.
    Clin Microbiol Infect. 2010
  7. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS.
    Roth O, Spreux-Varoquaux O, Bouchet S, Rousselot P, Castaigne S, Rigaudeau S, Raggueneau V, Therond P, Devillier P, Molimard M, Maneglier B.
    Clin Chim Acta. 2010
  8. Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study.
    Nègre-Pagès L, Grandjean H, Lapeyre-Mestre M, Montastruc JL, Fourrier A, Lépine JP, Rascol O, DoPaMiP Study Group.
    Mov Disord. 2010
  9. Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting.
    Pariente A, Sanctussy DJ, Miremont-Salamé G, Moore N, Haramburu F, Fourrier-Réglat A, l'Association Française des Centres Régionaux de Pharmacovigilance (CRPV).
    CNS Drugs. 2010
  10. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies.
    Verdoux H, Tournier M, Bégaud B.
    Acta Psychiatr Scand. 2010
  11. Prevention of type 2 diabetes induced by high fat diet in the C57BL/6J mouse by two medicinal plants used in traditional treatment of diabetes in the east of Algeria.
    Hamza N, Berke B, Cheze C, Agli AN, Robinson P, Gin H, Moore N.
    J Ethnopharmacol. 2010
  12. Mast cell adhesion to bronchial smooth muscle in asthma specifically depends on CD51 and CD44 variant 6.
    Girodet PO, Ozier A, Trian T, Begueret H, Ousova O, Vernejoux JM, Chanez P, Marthan R, Berger P, Tunon de Lara JM.
    Allergy. 2010
  13. Pharmacoepidemiological research using French reimbursement databases: yes we can!
    Martin-Latry K, Bégaud B.
    Pharmacoepidemiol Drug Saf. 2010
  14. Cutaneous adverse effects of ketoprofen for topical use: clinical patterns and costs.
    Noize P, Bénard-Laribière A, Aulois-Griot M, Moore N, Miremont-Salamé G, Haramburu F.
    Am J Clin Dermatol. 2010
  15. Antipsychotic use patterns in persons initially treated with mood stabilizers: a naturalistic study.
    Verdoux H, Cougnard A, Auleley GR, Deligne J, Blum-Boisgard C, Bégaud B, Tournier M.
    Pharmacopsychiatry. 2010
  16. Effect of engineered nanoparticles on vasomotor responses in rat intrapulmonary artery.
    Courtois A, Andujar P, Ladeiro Y, Ducret T, Rogerieux F, Lacroix G, Baudrimont I, Guibert C, Roux E, Canal-Raffin M, Brochard P, Marano F, Marthan R, Muller B.
    Toxicol Appl Pharmacol. 2010
  17. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users.
    Laharie D, Droz-Perroteau C, Bénichou J, Amouretti M, Blin P, Bégaud B, Guiard E, Dutoit S, Lamarque S, Moride Y, Depont F, Fourrier-Réglat A, Moore N.
    Br J Clin Pharmacol. 2010
  18. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M, Molimard M.
    Pulm Pharmacol Ther. 2010
  19. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).
    Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, Le Jeunne C, Naber D, Priori S, Sturkenboom M, Thibaut F, Peuskens J, Mittoux A, Tanghøj P, Toumi M, Moore ND, Mann RD.
    Acta Psychiatr Scand. 2010
  20. Improving pharmacovigilance in Europe.
    Moore N, Bégaud B.
    BMJ. 2010
  21. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
    Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS.
    J Clin Oncol. 2010
  22. A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application.
    Chauzit E, Bouchet S, Micheau M, Mahon FX, Moore N, Titier K, Molimard M.
    Ther Drug Monit. 2010
  23. Sleepiness, near-misses and driving accidents among a representative population of French drivers.
    Sagaspe P, Taillard J, Bayon V, Lagarde E, Moore N, Boussuge J, Chaumet G, Bioulac B, Philip P.
    J Sleep Res. 2010
  24. How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database.
    Latry P, Molimard M, Bégaud B, Martin-Latry K.
    Eur J Clin Pharmacol. 2010
  25. Concordance between prescriber- and patient-reported previous medical history and NSAID indication in the CADEUS cohort.
    Fourrier-Réglat A, Cuong HM, Lassalle R, Depont F, Robinson P, Droz-Perroteau C, Pariente A, Bégaud B, Blin P, Moore N.
    Pharmacoepidemiol Drug Saf. 2010
  26. Antihypertensive effects of Ocimum basilicum L. (OBL) on blood pressure in renovascular hypertensive rats.
    Umar A, Imam G, Yimin W, Kerim P, Tohti I, Berké B, Moore N.
    Hypertens Res. 2010
  27. Antispasmodic and antioxidant activities of fractions and bioactive constituent davidigenin isolated from Mascarenhasia arborescens.
    Desire O, Rivière C, Razafindrazaka R, Goossens L, Moreau S, Guillon J, Uverg-Ratsimamanga S, Andriamadio P, Moore N, Randriantsoa A, Raharisololalao A.
    J Ethnopharmacol. 2010
  28. Factors associated with persistence of cholinesterase inhibitor treatments in the elderly.
    Pariente A, Pinet M, Moride Y, Merlière Y, Moore N, Fourrier-Réglat A.
    Pharmacoepidemiol Drug Saf. 2010
  29. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data.
    Molimard M, Buhl R, Niven R, Le Gros V, Thielen A, Thirlwell J, Maykut R, Peachey G.
    Respir Med. 2010
  30. Side effects of spiramycin masquerading as local anesthetic toxicity during labor epidural analgesia.
    Julliac B, Théophile H, Begorre M, Richez B, Haramburu F.
    Int J Obstet Anesth. 2010
  31. Time course of mitochondrial metabolism alterations to repeated injections of bupivacaine in rat muscle.
    Nouette-Gaulain K, Bringuier S, Canal-Raffin M, Bernard N, Lopez S, Dadure C, Masson F, Mercier J, Sztark F, Rossignol R, Capdevila X.
    Can J Anaesth. 2010
  32. Niveau de preuve du suivi thérapeutique pharmacologique des inhibiteurs de tyrosine-kinase dans le traitement des leucémies myéloïdes chroniques.
    Bouchet S, Royer B, Le Guellec C, Titier K, Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique.
    Therapie. 2010
  33. Effectiveness of antibiotics for acute sinusitis in real-life medical practice.
    Blin P, Blazejewski S, Lignot S, Lassalle R, Bernard MA, Jayles D, Théophile H, Bénichou J, Demeaux JL, Ebbo D, Franck J, Moride Y, Peyramond D, Rouveix B, Sturkenboom M, Gehanno P, Droz C, Moore N.
    Br J Clin Pharmacol. 2010
  34. Are generic drugs really inferior medicines?
    Moore N, Berdaï D, Bégaud B.
    Clin Pharmacol Ther. 2010
  35. Omalizumab-induced decrease of Fc?RI expression in patients with severe allergic asthma.
    Chanez P, Contin-Bordes C, Garcia G, Verkindre C, Didier A, De Blay F, de Lara MT, Blanco P, Moreau JF, Robinson P, Bourdeix I, Trunet P, Le Gros V, Humbert M, Molimard M.
    Respir Med. 2010
  36. Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study.
    Ahmed I, Thiessard F, Miremont-Salamé G, Bégaud B, Tubert-Bitter P.
    Clin Pharmacol Ther. 2010
  37. Design and evaluation of a semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European EU-ADR project.
    Avillach P, Joubert M, Thiessard F, Trifirò G, Dufour JC, Pariente A, Mougin F, Polimeni G, Catania MA, Giaquinto C, Mazzaglia G, Fornari C, Herings R, Gini R, Hippisley-Cox J, Molokhia M, Pedersen L, Fourrier-Réglat A, Sturkenboom M, Fieschi M.
    Stud Health Technol Inform. 2010
  38. A potential competition bias in the detection of safety signals from spontaneous reporting databases.
    Pariente A, Didailler M, Avillach P, Miremont-Salamé G, Fourrier-Reglat A, Haramburu F, Moore N.
    Pharmacoepidemiol Drug Saf. 2010
  39. Insights into severe asthma control as assessed by guidelines, pulmonologist, patient, and partner.
    Molimard M, Vervloet D, Le Gros V, Bourdeix I, Ponthieux A.
    J Asthma. 2010
  40. Comparators (medicinal and non medicinal) for marketing authorization, for public health, for payers and at the European level.
    Berdaï D, Hotton JM, Lechat P, participates of Round Table n° 1 Giens XXV.
    Therapie. 2010
  41. Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need.
    de Sahb-Berkovitch R, Woronoff-Lemsi MC, Molimard M, participates of Round Table n° 7 Giens 2009.
    Therapie. 2010
  42. Terminologie utilisée concernant les bases de remboursement de l'assurance maladie en pharmaco-épidémiologie : une harmonisation nécessaire.
    Martin-Latry K, Cougnard A.
    Therapie. 2010
  43. When patients report diseases that prescribers seem unaware of: discordance between patient and physician reporting of risk-related previous history in NSAID users from the CADEUS study.
    Fourrier-Réglat A, Lacoin L, Pariente A, Lassalle R, Robinson P, Droz-Perroteau C, Bégaud B, Blin P, Moore ND.
    Clin Pharmacol Ther. 2010
  44. Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre.
    Théophile H, Arimone Y, Miremont-Salamé G, Moore N, Fourrier-Réglat A, Haramburu F, Bégaud B.
    Drug Saf. 2010
  45. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone.
    Crocq MA, Naber D, Lader MH, Thibaut F, Drici M, Everitt B, Hall GC, Le Jeunne C, Mittoux A, Peuskens J, Priori S, Sturkenboom M, Thomas SH, Tanghøj P, Toumi M, Mann R, Moore ND.
    Eur Neuropsychopharmacol. 2010
  46. Case series in drug safety: a review to determine characteristics and quality.
    Abou Chakra CN, Pariente A, Pinet M, Nkeng L, Moore N, Moride Y.
    Drug Saf. 2010